<DOC>
	<DOCNO>NCT01980823</DOCNO>
	<brief_summary>The purpose study determine effect combine metformin atorvastatin treatment patient newly diagnose breast cancer interval breast biopsy surgery . This study design ass whether tumor proliferation , measure natural log expression Ki-67 staining breast tumor cell , reduce follow approximately 2 week treatment combination metformin plus atorvastatin patient newly diagnose breast cancer .</brief_summary>
	<brief_title>Pre-Surgical Trial Combination Metformin Atorvastatin Newly Diagnosed Operable Breast Cancer</brief_title>
	<detailed_description>Breast cancer cell require energy homeostasis shift enhance anabolism enable rapid growth continue proliferation . The main energy regulatory system eukaryotes breast cancer cell AMP-activated kinase ( AMPK ) pathway . AMPK trigger change AMP/ATP ratio thus impact energy reserve requirement . AMPK pathway closely interact PI3K/AKT signal pathway , affect downstream function master regulator mTOR . Activation AMPK show vitro result inhibition proliferation various cancer cell line . Utilizing pre-surgical model , plan conduct pilot study 40 woman newly diagnose invasive breast cancer ductal carcinoma in-situ ( DCIS ) receive oral metformin atorvastatin daily interval diagnostic breast biopsy definitive breast surgery . The goal determine dual combination treatment metformin plus atorvastatin significantly impact tumor-based marker , proliferation , blood-based biomarkers .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Female subject histologicallyconfirmed operable invasive breast cancer DCIS , undergo core needle biopsy follow surgical excision least 2 week enrollment ≥ 5 mm imaging/pathology core ensure enough pre posttreatment tissue analysis Age ≥ 21 year . Breast cancer uncommon patient less age . No prior chemotherapy , radiation therapy , breast resection within 6 month study entry Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Signed inform consent Currently medication diabetes hypercholesterolemia Treatment investigational drug within 6 month study entry Strong CYP 3A4 inhibitor ( e.g. , clarithromycin , HIV protease inhibitor , itraconazole ) , give potential interaction atorvastatin Renal impairment creatinine &gt; 1.4 mg/dl Hepatic impairment : Aspartate transaminase ( AST ) / ( SGOT ) , Alanine Transaminase ( ALT ) / ( SGPT ) ≥ 2.5 x upper limit normal range ( ULN ) , OR Total bilirubin ≥ 1.5 x ULN ( subject Gilbert 's syndrome bilirubin 1.5 x ULN ) , OR Alkaline phosphatase &gt; 2.5 x ULN</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metformin</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Ki-67</keyword>
</DOC>